Chemotherapy/immunotherapy combination thwarts glioblastoma in pre-clinical research
Triple combination therapy kills glioblastoma in mice by putting an “eat me” signal to the immune system on the surface of the brain tumor cells, blocking an offsetting “don’t eat me” signal and protecting a cancer-killing immune response launched by the combination.
The brain tumor treatment, as reported in Nature Communications, more than doubled median survival of mice treated with all three drugs, compared to those treated...
Immunotherapy combination stifles pancreatic cancer in mouse models
Combining two immunotherapies caused tumor rejection in mouse models of pancreatic cancer and provided long-term immune memory that prevented...
Acute myeloid leukemia’s minimal residual disease targeted by Moon Shot
In patients with leukemia, complete remission after treatment is currently defined by the absence of cancer cells in a bone marrow biopsy...
Triple-negative breast cancer clinical trial allies with community oncologists
Triple-negative breast cancer (TNBC) is an aggressive disease that makes up roughly 15% to 20% of breast cancer diagnoses. Standard chemotherapy works for about half of these patients. But there is a significant need for personalized options to improve outcomes for all patients.
Through the Breast Cancer Moon Shot®, MD Anderson is conducting an innovative clinical trial, called ARTEMIS, to develop personalized therapy approaches...
